Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Garvan Institute Of Medical Research is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The busiest examiner for the company is TURPIN, ZACHARY MARK, who has 1 pending action. The prosecution is focused on 1 distinct examiner and 1 distinct art unit. With only 1 pending office action, the company's current USPTO engagement is highly centralized.
For a practitioner, the concentration in the Biotechnology & Pharmaceuticals area means that the 1 distinct examiner's review will be the only factor in the resolution of the 1 pending action. The 1 pending office action represents the entirety of the active workload, so there is no diversification across different art units. This centralized prosecution environment allows for a very specific legal strategy but also increases the risk associated with the 1 distinct examiner's personal interpretation. Practitioners should focus on the 1 distinct art unit's technical guidelines and the specific examination style of the assigned examiner to resolve the 1 pending action successfully.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TURPIN, ZACHARY MARK | 1 | 4.0% | -5.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17127159 | SEQUENCING CONTROLS | TURPIN, ZACHARY MARK | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17127159 | SEQUENCING CONTROLS | TURPIN, ZACHARY MARK | 1682 | §103§112DP | Final Rejection | — | Pending | Dec 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGarvan Institute Of Medical Research has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Zachary Mark Turpin has the most, with 1 of Garvan Institute Of Medical Research's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
